(Q36628549)

English

Fosamprenavir or atazanavir once daily boosted with ritonavir 100 mg, plus tenofovir/emtricitabine, for the initial treatment of HIV infection: 48-week results of ALERT.

scientific article published on 28 March 2008

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

15 August 2017

Fosamprenavir or atazanavir once daily boosted with ritonavir 100 mg, plus tenofovir/emtricitabine, for the initial treatment of HIV infection: 48-week results of ALERT. (English)

1 reference

Europe PubMed Central

15 August 2017

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

tenofovir/emtricitabine

1 reference

based on heuristic

inferred from title

Margaret A Fischl

4

object named as

Margaret A Fischl

1 reference

Europe PubMed Central

15 August 2017

author name string

Kimberly Y Smith

1

1 reference

Europe PubMed Central

15 August 2017

Winkler G Weinberg

2

1 reference

Europe PubMed Central

15 August 2017

Edwin DeJesus

3

1 reference

Europe PubMed Central

15 August 2017

Qiming Liao

5

1 reference

Europe PubMed Central

15 August 2017

Lisa L Ross

6

1 reference

Europe PubMed Central

15 August 2017

Gary E Pakes

7

1 reference

Europe PubMed Central

15 August 2017

Keith A Pappa

8

1 reference

Europe PubMed Central

15 August 2017

C Tracey Lancaster

9

1 reference

Europe PubMed Central

15 August 2017

ALERT (COL103952) Study Team

10

1 reference

Europe PubMed Central

15 August 2017

language of work or name

1 reference

based on heuristic

inferred from title

publication date

28 March 2008

1 reference

Europe PubMed Central

15 August 2017

AIDS Research and Therapy

1 reference

Europe PubMed Central

15 August 2017

5

1 reference

Europe PubMed Central

15 August 2017

5

1 reference

Europe PubMed Central

15 August 2017

https://scigraph.springernature.com/pub.10.1186/1742-6405-5-5

0 references

Tenofovir-associated Fanconi syndrome: review of the FDA adverse event reporting system

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2365957

30 September 2017

British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy (2006).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2365957

30 September 2017

Plasma amprenavir pharmacokinetics and tolerability following administration of 1,400 milligrams of fosamprenavir once daily in combination with either 100 or 200 milligrams of ritonavir in healthy volunteers

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2365957

30 September 2017

Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2365957

30 September 2017

Pharmacokinetics of tenofovir disoproxil fumarate and ritonavir-boosted saquinavir mesylate administered alone or in combination at steady state

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2365957

30 September 2017

Fosamprenavir : clinical pharmacokinetics and drug interactions of the amprenavir prodrug

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2365957

30 September 2017

Lack of pharmacokinetic drug interaction between tenofovir disoproxil fumarate and nelfinavir mesylate

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2365957

30 September 2017

Clinical pharmacokinetics and summary of efficacy and tolerability of atazanavir

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2365957

30 September 2017

Interactions between atazanavir-ritonavir and tenofovir in heavily pretreated human immunodeficiency virus-infected patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2365957

30 September 2017

A review of low-dose ritonavir in protease inhibitor combination therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2365957

30 September 2017

Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2365957

30 September 2017

The effect of ritonavir on saquinavir plasma concentration is independent of ritonavir dosage: combined analysis of pharmacokinetic data from 97 subjects

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2365957

30 September 2017

Pharmacokinetic modeling and simulations of interaction of amprenavir and ritonavir

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2365957

30 September 2017

Results of a phase 2 clinical trial at 48 weeks (AI424-007): a dose-ranging, safety, and efficacy comparative trial of atazanavir at three doses in combination with didanosine and stavudine in antiretroviral-naive subjects

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2365957

28 June 2018

Tenofovir use is associated with a reduction in calculated glomerular filtration rates in the Swiss HIV Cohort Study.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2365957

20 September 2018

Greater tenofovir-associated renal function decline with protease inhibitor-based versus nonnucleoside reverse-transcriptase inhibitor-based therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2365957

20 September 2018

Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society-USA panel.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2365957

20 September 2018

Comparison of once-daily atazanavir with efavirenz, each in combination with fixed-dose zidovudine and lamivudine, as initial therapy for patients infected with HIV.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2365957

20 September 2018

Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents, January 28, 2000 by the Panel on Clinical Practices for Treatment of HIV Infection.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2365957

20 September 2018

1 reference

https://pubmed.ncbi.nlm.nih.gov/18373851

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effect of diclofenac on renal function and prostacyclin generation after surgery

1 reference

https://pubmed.ncbi.nlm.nih.gov/18373851

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1186/1742-6405-5-5

1 reference

Europe PubMed Central

15 August 2017

Dimensions Publication ID

0 references

1 reference

Europe PubMed Central

15 August 2017

1 reference

Europe PubMed Central

15 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q36628549&oldid=1946345480"